Fox Investigation for New Discovery of Biomarkers

Inclusion Criteria (PD Subjects): * Subjects must have bradykinesia and rigidity. * Current or history of well documented resting tremor. * Unilateral onset or persistent asymmetry. * A well established response to dopaminergic agents including the presence of levodopa induced dyskinesia for at least 3 years according to treating physician's judgment. * Subject has progressive PD of 5 to 18 years of duration from the onset of symptoms. * Male or female age of onset of PD 50 to 70 by history. Current ages would range from 55 to 93 based on #5 and #6 requirements. * Ability to provide written informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations. * Willing and able to comply with scheduled visits, required study procedures and laboratory tests. Exclusion Criteria (PD Subjects): * Family history of PD in first degree relatives. * Ashkenazi Jewish subject (defined as all 4 grandparents being Ashkenazi Jewish) will be excluded because of the high likelihood of genetic forms of PD (LRRK2) and GBA), unless these have been already excluded by genetic testing. * Has others serious neurological disorders (clinically significant stroke, brain tumor, hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis, repeated head trauma). * Has early severe autonomic involvement. Symptomatic orthostatic, hypotension or urinary incontinence within one year of onset of disease symptom. * Current treatment with anticoagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture. * Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. * Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation. * Use of investigational drugs or devices within 60 days prior to baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10). * Has lower body predominant symptoms. * Has supra-nuclear gaze palsy, CG sign, corticospinal track signs. Inclusion Criteria (HC Subjects): * Male or female age 55 to 93 years at visit 1. * Ability to provide written informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations. * Willing and able to comply with scheduled visits, required study procedures and laboratory tests. Exclusion Criteria (HC Subjects): * Family history of PD in first degree relatives. * Ashkenazi Jewish subject (defined as all 4 grandparents being Ashkenazi Jewish) will be excluded because of the high likelihood of genetic forms of PD (LRRK2) and GBA), unless these have been already excluded by genetic testing. * Has other serious neurological disorders (clinically significant stroke, brain tumor, hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis, repeated head trauma). * Has a history of cancer, autoimmune disorder, liver disease, or hematological disorders within the past 5 years. * Has early severe autonomic involvement: symptomatic orthostatic hypotension or urinary incontinence within one year of onset of disease symptom. * Current treatment with anticoagulants (e.g., Coumadin, heparin) that might preclude safe completion of the lumbar puncture. * Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. * Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation. * Use of investigational drugs or devices within 60 days prior to baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10). * MoCA score \<26.